X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the term of the license agreement, the companies plan to combine Kelonia's iGPS with Xyphos' ACCEL technology to develop innovative in vivo CAR-T Cell therapies for Immuno-oncology.
Lead Product(s): CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Kelonia Therapeutics
Deal Size: $840.0 million Upfront Cash: $40.0 million
Deal Type: Licensing Agreement February 15, 2024
Details:
The companies will jointly conduct research activities to identify and optimize proprietary LENS Integrated Intelligence Technology in silico generated antibodies, targeting an undisclosed target in the TME, as potential therapeutic development candidates.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Talem Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2023
Details:
The collaboration will leverage Phanes’ proprietary technology platforms, PACbody and SPECpair, in the evaluation of cell therapies in oncology. The company has its proprietary technology platforms to develop novel biologics that address high unmet medical needs in cancer.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Phanes Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 06, 2023
Details:
GO will lead the collaboration to discover high-affinity antibodies against the two targets, and Astellas will be responsible for research activities, clinical development and commercialization of the therapeutics derived from the antibodies for Immuno-Oncology.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: GO Therapeutics
Deal Size: $783.5 million Upfront Cash: $20.5 million
Deal Type: Collaboration June 01, 2022
Details:
The agreement covers VIVEbiotech long-term supplying lentiviral vectors for Xyphos’ upcoming clinical trial of its lead convertibleCAR-T™ program. This involves VIVEbiotech manufacturing lentiviral vectors for both preclinical and clinical phases.
Lead Product(s): Lentiviral vectors,convertible CAR-T cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Recipient: VIVEbiotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
